
Opinion|Videos|October 23, 2023
Mitigating Cardiovascular Risk In Obesity
Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.
Advertisement
Episodes in this series
1:14 Obesity and cardiovascular risk
3:28 Topline findings for semaglutide in the SELECT trial
7:15 CV risk reduction with semaglutide
8:54 Perspectives on cost-benefit for GLP-1 in obesity
14:14 Outcomes from STEP HFpEF trial
16:44 Considerations for using GLP-1 agonists
20:54 Need to address inequity in access to obesity medications
26:44 Investigational therapies for obesity with potential for CV benefits
30:00 Combination therapy for obesity and CV risk
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA News Recap: Novel Drug Approvals in First Half of 2026
2
4 Nephrology Headlines You Missed in June 2026
3
6 Cardiology Headlines You Missed in June 2026
4
Heterogeneity, Refractory Symptoms, and Multidimensional Care in Pediatric Functional Constipation and IBS-C
5

















































































